Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Daniel W Sherbenou

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Biography 
    Collapse awards and honors
    2014 - 2015Young Investigator Award - Grand Multiple Myeloma Translational Initiative, University of California, San Francisco
    1998 - 1999Undergraduate Honors Thesis, University of Colorado at Boulder
    2016 - 2016Paul O'Hara II Seed Grant, University of Colorado Cancer Center
    2016 - 20182016 Young Investigator Award, NCCN Foundation
    2017 - 2019Loan Repayment Program, National Cancer Institute
    2018 - 2018Translational Research Training in Hematology, European Hematology Association/American Society of Hematology
    2018 - 2019Junior Faculty CO-PILOT Award, Colorado Clinical & Translational Sciences Institute
    2018 - 2023K08CA222704 Clinical Investigator Award, National Institutes of Health (National Cancer Institute)

    Collapse Overview 
    Collapse overview
    As an undergraduate at the University of Colorado, I started by scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In the MD/PhD program at Oregon Heath & Science University, I focused on translational leukemia research. Under the mentorship of Drs. Brian Druker and Michael Deininger, I focused on chronic myeloid leukemia. My thesis evaluated mechanisms of kinase inhibitor resistance in patients treated with imatinib (Gleevec). In oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducting preclinical analyses of a novel ADC for multiple myeloma, with hope this this to soon lead to transition to the clinic. Now a faculty member at UC Denver in the Hematology division, I will oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and will care for patients with myeloma and related plasma cell disorders of Colorado and adjoining areas.

    Collapse Research 
    Collapse research activities and funding
    K08CA222704     (SHERBENOU, DANIEL)Aug 8, 2018 - Jul 31, 2023
    Targeting Cancer Initiating Cells in Multiple Myeloma
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Keller AL, Sherbenou DW, Forsberg PA, Mark TM. Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. Front Oncol. 2022; 12:925818. PMID: 35814431.
      View in: PubMed
    2. Davis LN, Sherbenou DW. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel). 2021 Apr 02; 13(7). PMID: 33918370.
      View in: PubMed
    3. Sherbenou D, Stalker M, Forsberg P, Mark TM. Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e630-e634. PMID: 33863694.
      View in: PubMed
    4. Walker ZJ, Idler BM, Davis LN, Stevens BM, VanWyngarden MJ, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, Jordan CT, Mark TM, Forsberg PA, Sherbenou DW. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clin Cancer Res. 2021 02 01; 27(3):819-830. PMID: 33109736.
      View in: PubMed
    5. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res. 2020 11 15; 26(22):6028-6038. PMID: 32917735.
      View in: PubMed
    6. Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, Mark T, Forsberg P, Sherbenou D, Hammes A, Rabinovitch R, Smith CA, Gutman JA. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020 05 26; 4(10):2227-2235. PMID: 32442301.
      View in: PubMed
    7. Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langou√ęt-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, Jordan CT, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020 04 28; 4(8):1628-1639. PMID: 32311014.
      View in: PubMed
    8. Harnoss JM, Le Thomas A, Shemorry A, Marsters SA, Lawrence DA, Lu M, Chen YA, Qing J, Totpal K, Kan D, Segal E, Merchant M, Reichelt M, Ackerly Wallweber H, Wang W, Clark K, Kaufman S, Beresini MH, Laing ST, Sandoval W, Lorenzo M, Wu J, Ly J, De Bruyn T, Heidersbach A, Haley B, Gogineni A, Weimer RM, Lee D, Braun MG, Rudolph J, VanWyngarden MJ, Sherbenou DW, Gomez-Bougie P, Amiot M, Acosta-Alvear D, Walter P, Ashkenazi A. Disruption of IRE1a through its kinase domain attenuates multiple myeloma. Proc Natl Acad Sci U S A. 2019 08 13; 116(33):16420-16429. PMID: 31371506.
      View in: PubMed
    9. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep; 6(9):e459-e469. PMID: 31327687.
      View in: PubMed
    10. Forsberg PA, Rossi AC, Boyer A, Tegnestam L, Pearse RN, Perry A, Pekle KA, Jayabalan D, Ely S, Boussi L, Sherbenou DW, Williams C, Allan JN, Coleman M, Niesvizky R, Mark TM. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019 05; 94(5):539-545. PMID: 30740766.
      View in: PubMed
    11. Forsberg PA, Hammes A, Abbott D, Sherbenou DW, Rossi A, Jayabalan D, Niesvizky R, Mark TM, Ely S. Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. Leuk Lymphoma. 2019 08; 60(8):2085-2087. PMID: 30632821.
      View in: PubMed
    12. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17). PMID: 30185663.
      View in: PubMed
    13. Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, Sherbenou D, Rabinovitch R, Hammes A, Gutman JA. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. Biol Blood Marrow Transplant. 2018 08; 24(8):1671-1677. PMID: 29684565.
      View in: PubMed
    14. Lee NK, Zhang Y, Su Y, Bidlingmaier S, Sherbenou DW, Ha KD, Liu B. Cell-type specific potent Wnt signaling blockade by bispecific antibody. Sci Rep. 2018 01 15; 8(1):766. PMID: 29335534.
      View in: PubMed
    15. Sherbenou DW, Mark TM, Forsberg P. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):545-554. PMID: 28734795.
      View in: PubMed
    16. Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937. PMID: 28285081.
      View in: PubMed
    17. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653. PMID: 27841764.
      View in: PubMed
    18. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015 Mar; 29(2):81-91. PMID: 25294123.
      View in: PubMed
    19. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010 Oct 28; 116(17):3278-85. PMID: 20519627.
      View in: PubMed
    20. Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008 Jun; 22(6):1184-90. PMID: 18354488.
      View in: PubMed
    21. Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007 Aug; 117(8):2067-74. PMID: 17671641.
      View in: PubMed
    22. Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007 Mar; 21(3):489-93. PMID: 17252009.
      View in: PubMed
    23. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006 Dec 01; 66(23):11156-65. PMID: 17145859.
      View in: PubMed
    24. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6987-93. PMID: 16203792.
      View in: PubMed
    Sherbenou's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description

    Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)